Cargando…
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
BACKGROUND: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non‐HA population. As new therapies are introduced, a uniform approach to the assessment of mortality is required for comprehensive evaluation of risk–benefit pr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756842/ https://www.ncbi.nlm.nih.gov/pubmed/33331042 http://dx.doi.org/10.1111/jth.15186 |
_version_ | 1783626630352076800 |
---|---|
author | Pipe, Steven W. Kruse‐Jarres, Rebecca Mahlangu, Johnny N. Pierce, Glenn F. Peyvandi, Flora Kuebler, Peter De Ford, Christian Sanabria, Fabián Ko, Richard H. Chang, Tiffany Hay, Charles R. M. |
author_facet | Pipe, Steven W. Kruse‐Jarres, Rebecca Mahlangu, Johnny N. Pierce, Glenn F. Peyvandi, Flora Kuebler, Peter De Ford, Christian Sanabria, Fabián Ko, Richard H. Chang, Tiffany Hay, Charles R. M. |
author_sort | Pipe, Steven W. |
collection | PubMed |
description | BACKGROUND: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non‐HA population. As new therapies are introduced, a uniform approach to the assessment of mortality is required for comprehensive evaluation of risk–benefit profiles, timely identification of emerging safety signals, and comparisons between treatments. OBJECTIVES: Develop and test a framework for consistent reporting and analysis of mortality across past, current, and future therapies. PATIENTS/METHODS: We identified known causes of mortality in PwcHA through literature review, analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, and expert insights. Leading causes of death in general populations are those recognized by the Centers for Disease Control and Prevention and the World Health Organization. We developed an algorithm for assessing fatalities in PwcHA and used this to categorize FAERS data as a proof of concept. RESULTS: PwcHA share mortality causes with the non‐HA population including cardiovascular disease, malignancy, infections, pulmonary disease, dementias, and trauma/suicide. Causes associated with HA include hemorrhage, thrombosis, human immunodeficiency virus, hepatitis C virus, and liver dysfunction. We propose an algorithm employing these classes to categorize fatalities and use it to classify FAERS fatality data between 01/01/2000 and 03/31/2020; the most common causes were hemorrhage (22.2%) and thrombosis (10.4%). CONCLUSIONS: A conceptual framework for examining mortality in PwcHA receiving any hemophilia therapy is proposed to analyze and interpret fatalities, enabling consistent and objective assessment. Application of the framework using FAERS data suggests a generally consistent pattern of reported mortality across HA treatments, supporting the utility of this unified approach. |
format | Online Article Text |
id | pubmed-7756842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77568422020-12-28 Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database Pipe, Steven W. Kruse‐Jarres, Rebecca Mahlangu, Johnny N. Pierce, Glenn F. Peyvandi, Flora Kuebler, Peter De Ford, Christian Sanabria, Fabián Ko, Richard H. Chang, Tiffany Hay, Charles R. M. J Thromb Haemost Original Articles BACKGROUND: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non‐HA population. As new therapies are introduced, a uniform approach to the assessment of mortality is required for comprehensive evaluation of risk–benefit profiles, timely identification of emerging safety signals, and comparisons between treatments. OBJECTIVES: Develop and test a framework for consistent reporting and analysis of mortality across past, current, and future therapies. PATIENTS/METHODS: We identified known causes of mortality in PwcHA through literature review, analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, and expert insights. Leading causes of death in general populations are those recognized by the Centers for Disease Control and Prevention and the World Health Organization. We developed an algorithm for assessing fatalities in PwcHA and used this to categorize FAERS data as a proof of concept. RESULTS: PwcHA share mortality causes with the non‐HA population including cardiovascular disease, malignancy, infections, pulmonary disease, dementias, and trauma/suicide. Causes associated with HA include hemorrhage, thrombosis, human immunodeficiency virus, hepatitis C virus, and liver dysfunction. We propose an algorithm employing these classes to categorize fatalities and use it to classify FAERS fatality data between 01/01/2000 and 03/31/2020; the most common causes were hemorrhage (22.2%) and thrombosis (10.4%). CONCLUSIONS: A conceptual framework for examining mortality in PwcHA receiving any hemophilia therapy is proposed to analyze and interpret fatalities, enabling consistent and objective assessment. Application of the framework using FAERS data suggests a generally consistent pattern of reported mortality across HA treatments, supporting the utility of this unified approach. John Wiley and Sons Inc. 2020-12-16 2021-01 /pmc/articles/PMC7756842/ /pubmed/33331042 http://dx.doi.org/10.1111/jth.15186 Text en © 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Pipe, Steven W. Kruse‐Jarres, Rebecca Mahlangu, Johnny N. Pierce, Glenn F. Peyvandi, Flora Kuebler, Peter De Ford, Christian Sanabria, Fabián Ko, Richard H. Chang, Tiffany Hay, Charles R. M. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database |
title | Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database |
title_full | Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database |
title_fullStr | Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database |
title_full_unstemmed | Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database |
title_short | Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database |
title_sort | establishment of a framework for assessing mortality in persons with congenital hemophilia a and its application to an adverse event reporting database |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756842/ https://www.ncbi.nlm.nih.gov/pubmed/33331042 http://dx.doi.org/10.1111/jth.15186 |
work_keys_str_mv | AT pipestevenw establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT krusejarresrebecca establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT mahlangujohnnyn establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT pierceglennf establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT peyvandiflora establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT kueblerpeter establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT defordchristian establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT sanabriafabian establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT korichardh establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT changtiffany establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase AT haycharlesrm establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase |